文献速递骨质疏松与钙磷/甲状旁腺

铁过载患者骨折风险增加:一项基于人群的匹配队列研究

Increased Risk of Fracture Among Patients With Iron Overload: A Population-based Matched Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究利用英国全科医疗数据库,纳入2010至2022年间铁蛋白>1000 µg/L或诊断为铁过载疾病的患者,按1:10匹配对照,采用时变混杂因素调整的Cox模型分析骨折风险。结果显示铁过载患者任何骨折风险增加55%(HR 1.55 [1.42-1.68]),椎体骨折风险最高(HR 1.97 [1.63-2.10]),且铁蛋白>1000 µg/L者风险更高。

要点

  • 铁过载患者任何骨折风险增加55%(HR 1.55 [1.42-1.68]),椎体骨折风险最高(HR 1.97 [1.63-2.10])。
  • 铁蛋白>1000 µg/L者任何骨折风险增加91%(HR 1.91 [1.73-2.16]),椎体骨折风险增加2.5倍(HR 2.51 [2.01-3.12])。
  • 铁蛋白未升高者任何部位骨折风险均未增加,骨折风险在两性间相似。

核心结论

  • 这项大型人群队列研究发现铁过载与骨折风险增加55%相关,风险在实验室确认铁过载的患者中最高,提示临床医生应考虑对血清铁蛋白>1000 µg/L的患者启动骨质疏松治疗以降低骨折风险。

研究设计与样本

  • 使用英国全科医疗数据库(The Healthcare Improvement Network,Cegedim数据库),识别2010至2022年间年龄>18岁、铁蛋白>1000 µg/L或具有铁过载疾病诊断代码的患者,以首次铁蛋白升高或诊断代码日期为索引日期,按最多1:10匹配对照。
  • 采用时变混杂因素调整的Cox比例风险模型估计风险比(HR)和95%置信区间,按骨质疏松性骨折部位(髋部、椎体、肱骨、前臂)、基线血清铁蛋白升高(铁蛋白>1000 µg/L)及性别进行分层分析。

主要发现

  • 共识别20 264例合格患者和192 956例对照。
  • 铁过载患者任何骨折风险增加55%(HR 1.55 [1.42-1.68])。
  • 所有部位骨折风险均增加,椎体骨折风险最高(HR 1.97 [1.63-2.10])。
  • 铁蛋白>1000 µg/L患者任何骨折风险增加91%(HR 1.91 [1.73-2.16]),椎体骨折风险增加2.5倍(HR 2.51 [2.01-3.12])。
  • 血清铁蛋白未升高患者任何部位骨折风险均未增加,骨折风险在两性间相似。

临床怎么用

  • 作者认为,临床医生应考虑对血清铁蛋白>1000 µg/L的患者启动骨质疏松治疗以降低骨折风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Iron overloading disorders are associated with decreased bone mineral density. However, evidence on fracture risk is scarce. Therefore, we evaluated the risk of fracture associated with iron overload disorders compared to matched controls. METHODS: Using The Healthcare Improvement Network, a Cegedim database of UK general practice data, we identified patients >18 years with elevated iron (ferritin value >1000 µg/L) or an eligible diagnosis code for iron overloading disorders between 2010 and 2022. The first date of elevated iron or a diagnosis code defined the index date for iron overload patients, who were matched with up to 10 controls. Time-varying confounder-adjusted Cox proportional hazard models estimated the hazard ratios (HRs) and 95% confidence intervals. Analyses were stratified by osteoporotic fracture site (hip, vertebral, humerus, forearm) and evidence of elevated serum ferritin at baseline (ferritin >1000 µg/L), and sex. RESULTS: We identified 20 264 eligible patients and 192 956 controls. Overall, there was a 55% increased risk of any fracture among iron overload patients (HR 1.55 [1.42-1.68]). Fracture risk was increased at all sites, with the highest risk observed for vertebral fractures (HR 1.97 [1.63-2.10]). Patients with ferritin >1000 µg/L had a 91% increased risk of any fracture (HR 1.91 [1.73-2.16]) and a 2.5-fold increased risk of vertebral fractures (HR 2.51 [2.01-3.12]). There was no increased risk among patients without elevated serum ferritin at any site. Fracture risk was similar between sexes. DISCUSSION: This large population-based cohort study found a 55% increased risk of fracture associated with iron overload. The risk was highest among patients with laboratory-confirmed iron overload, highlighting the importance for clinicians to consider initiating osteoporosis therapy in patients with serum ferritin >1000 µg/L to minimize fracture risk.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Burden AM, Martinez-De la Torre A, Burkard T, et al. Increased Risk of Fracture Among Patients With Iron Overload: A Population-based Matched Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 39556493. doi:10.1210/clinem/dgae807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。